Comparative Retrospective Analysis of pNETs Treatment with Everolimus (E) and Sunitinib (S). Abstract #1702

Introduction: Two targeted compounds are validated for treatment of pNETs – E and S.
Aim(s): We performed retrospective analysis of pts with pNETs treated with E or S. Previously these pts have not been treated with either of these drugs.
Materials and methods: 20 pts with progressive pNETs (G1,G2) were treated with E and 16 pts with S 37,5 mg or 50mg dose regimen. All pts were on treatment with long acting octreotide. The mean age was 47 years in E group and 53 in S group. Most pts had liver metastases – 17/20 (85%) in E group and 15/16 (93%) in S group, regional l/nodes – in 6/20 (30%) and 6/16 (38%) and not regional l/nodes in – 4/20 (20%) and 4/16 (25%) pts respectively. Only 4 pts in each group were heavily pretreated with 3 or more lines of chemotherapy. G1 tumor was in 3 pts (E group) and no one in S group. Cytoreductive surgery was performed in 8 (40%) pts (E) and 9 (56%) pts (S).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Vera Gorbunova

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia
Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Anna Kuznetsova
#1294 The Efficacy and Safety of Sunitinib in Heavily Pretreated Patients with NETs. National Cancer Research Center Experience.
Introduction: There was done monocentral trial. 19 pts with progressive well differentiated NETs (G1,G2) were treated with sunitinib
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Anastacia Odintsova
#1275 Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: prof Vera Gorbunova
#1337 O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Svetlana Polozkova
#2869 Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors
Introduction: A 33-year-old patient with pancreatic neuroendocrine tumor (NET) G2 revealed progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal space 1.5 months after surgical treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Anna Kuznetsova